Paul Hastings LLP advised the underwriters in connection with Lexeo Therapeutics’ IPO. Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Sonia Carcano
…
This content is for Standard 1 Year members only. LoginJoin Now